Holen Sie sich die Stockscreener-App
1.41
2.17%
0.03
Handel nachbörslich:
1.43
0.02
+1.42%
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
Analyzing the Impact of Earnings Reports on MaxCyte Inc Inc. (MXCT) Price Performance - investchronicle.com
Signal strength of MaxCyte Inc. stock in tech scannersWeekly Trade Analysis & Capital Efficiency Focused Ideas - Newser
Maxcyte Stock Soars 10.87% on Insider Buying - AInvest
Volume spikes in MaxCyte Inc. stock – what they meanIPO Watch & Weekly Top Stock Performers List - Newser
Custom strategy builders for tracking MaxCyte Inc.Treasury Yields & Safe Swing Trade Setup Alerts - Newser
Douglas buys $111k in Maxcyte shares By Investing.com - Investing.com South Africa
Masoud Maher buys Maxcyte (MXCT) shares worth $102,915 - Investing.com
Maxcyte CFO Swirsky buys $64.5k in shares - Investing.com
Erck Stanley C, Maxcyte director, buys $137k in MXCT stock - Investing.com
Maxcyte Director and CFO Make Significant Stock Purchases. - AInvest
MaxCyte Executives and Directors Acquire Shares - TradingView
Should value investors consider MaxCyte Inc.Game-Changing Investment Alerts - thegnnews.com
What machine learning models say about MaxCyte Inc.2025 Winners & Losers & AI Driven Stock Reports - Newser
Will MaxCyte Inc. continue its uptrendJuly 2025 Trends & Stepwise Trade Signal Implementation - Newser
MaxCyte (NASDAQ:MXCT) Earns Neutral Rating from BTIG Research - Defense World
MaxCyte Inc. Breaks Losing Streak — Is the Trend ReversingFree Premium Stock Market Reports - beatles.ru
Chart based exit strategy for MaxCyte Inc.Oversold Stock Bounce Playbook Generator - Newser
Chartists Watching For Breakout in MaxCyte Inc.Weekly Return Pick Forecast Reports Show Trend - beatles.ru
MaxCyte Chief Commercial Officer Departs Amid Severance Agreement - TipRanks
BTIG Downgrades MaxCyte to Neutral Citing Ongoing Challenges for Cell and Gene Therapy Customers - AInvest
MaxCyte Shares Plummet After Analyst Downgrades and Missed Earnings Estimates - AInvest
MaxCyte Shares Fall After BTIG Downgrade - MarketScreener
MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments. - AInvest
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
BTIG Downgrades MaxCyte to Neutral From Buy - MarketScreener
MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns - Investing.com Nigeria
MaxCyte signs platform license agreement with Adicet Bio for Gamma Delta T cell therapies - SelectScience
MaxCyte signs platform license agreement with Adicet Bio - MSN
MaxCyte (NASDAQ:MXCT) Lowered to Sell Rating by Wall Street Zen - Defense World
MaxCyte Inc Q2 2025 Earnings: Revenue Falls Short at $8.5 Million, Net Loss Widens to $12.4 Million - AInvest
MaxCyte, Inc. (NASDAQ:MXCT) Q2 2025 Earnings Call Transcript - Insider Monkey
Maxcyte, Inc. shares rise 1.40% after-hours despite William Blair downgrading to Market Perform. - AInvest
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates - MSN
MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation - MSN
Maxcyte's 31% Intraday Plunge: Earnings Woes and Sector Turbulence Spark Investor Panic - AInvest
MaxCyte Disappoints With Lower Revenue And Guidance For 2025 - Finimize
William Blair Downgrades MaxCyte to Market Perform From Outperform - MarketScreener
MaxCyte downgraded to Market Perform from Outperform at William Blair - TipRanks
Maxcyte, Inc. shares fall 11.76% premarket after Q2 revenue misses analyst estimates. - AInvest
MaxCyte stock downgraded by William Blair to Market Perform on weak guidance - Investing.com Australia
MaxCyte's Q2 2025 Earnings Call: Unpacking Key Contradictions in Growth and Manufacturing Strategy - AInvest
MaxCyte Updates 2025 Revenue Guidance to $29.5M-$32.5M Amid Customer Program Consolidation - AInvest
Earnings call transcript: MaxCyte misses Q2 revenue forecast amidst stock dip - Investing.com
MaxCyte (MXCT) Q2 Revenue Drops 18% - AOL.com
What MACD and RSI say about MaxCyte Inc.Algorithmic Prediction of Market Breakouts - Newser
Maxcyte 2025 Q2 Earnings Worse Performance as Net Loss Widens 31.8% - AInvest
MaxCyte Q3 2025 presentation slides: SPL portfolio expands despite market challenges - Investing.com Nigeria
MaxCyte Q3 2025 presentation slides: SPL portfolio expands despite market challenges By Investing.com - Investing.com South Africa
Cell-engineering firm MaxCyte Q2 revenue misses analyst estimates - MarketScreener
MaxCyte Reports Q2 2025 Financial Results - TipRanks
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance - Morningstar
Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 52,831 MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Partners with Adicet Bio for Gamma Delta T Cell Therapy Platform License Agreement - AInvest
MaxCyte (MXCT) Projected to Post Quarterly Earnings on Wednesday - Defense World
MaxCyte Inks Strategic Platform License with Adicet Bio, Entitled to Licensing Fees and Revenue - AInvest
Maxcyte signs platform license agreement with Adicet Bio - MarketScreener
MaxCyte Signs Platform License Agreement with Adicet Bio - The Manila Times
MaxCyte, Adicet Bio Sign Strategic Platform License Agreement - AInvest
2.30%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):